Suppression of Neurological Deterioration in the APP1.PSEN1/APOE4 Murine Model of Alzheimer's Disease by AAV-Mediated Expression of APOE2 Christchurch

被引：0
|
作者：
Gunaydin, Caner [1 ]
Lephart, Hailey C. [1 ]
Stiles, Katie M. [1 ]
Hackett, Neil R. [1 ]
Kaminsky, Stephen M. [1 ]
Sondhi, Dolan [1 ]
Crystal, Ronald G. [1 ]
机构：
[1] Weill Cornell Med, Dept Med Genet, New York, NY USA
来源：
MOLECULAR THERAPY | 2023年 / 31卷 / 04期
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
816
引用
收藏
页码：402 / 403
页数：2
相关论文
共 50 条
  • [1] AAV-Mediated APOE4 Gene Silencing to Treat Homozygous APOE4-Associated Alzheimer's Disease
    Karan, Kalpita R.
    Kebret, Mara R.
    Hackett, Neil R.
    Crystal, Ronald G.
    MOLECULAR THERAPY, 2024, 32 (04) : 533 - 533
  • [2] Differential Signaling Mediated by ApoE2, ApoE3, and ApoE4 in Human Neurons Parallels Alzheimer's Disease Risk
    Huang, Yu-Wen Alvin
    Zhou, Bo
    Nabet, Amber M.
    Wernig, Marius
    Sudhof, Thomas C.
    JOURNAL OF NEUROSCIENCE, 2019, 39 (37): : 7408 - 7427
  • [3] Commentary: Differential Signaling Mediated by ApoE2, ApoE3, and ApoE4 in Human Neurons Parallels Alzheimer's Disease Risk
    Dzianok, Patrycja
    Kublik, Ewa
    FRONTIERS IN AGING NEUROSCIENCE, 2020, 12
  • [4] Second Generation APOE2+APOE4- AAV-Mediated Gene Therapy for APOE Homozygotes at Risk for Alzheimer's Disease
    Montel, Rachel
    Frenk, Esther
    Crystal, Ronald G.
    Stiles, Katie M.
    MOLECULAR THERAPY, 2021, 29 (04) : 167 - 168
  • [5] Ependyma-Derived ApoE2 Protects Against Alzheimer's Disease Phenotypes in the Presence of ApoE4
    Jackson, Rosemary J.
    Carrell, Ellie
    Keiser, Megan S.
    Meltzer, Jonah C.
    Fykstra, Dustin P.
    Dierksmeier, Steven E.
    Hajizadeh, Soroush
    Kreuzer, Johannes
    Morris, Robert
    Melloni, Alexandra
    Nakajima, Tsuneo
    Tecedor, Luis
    Ranum, Paul T.
    Chen, Yonghong
    Holtzman, David M.
    Haas, Wilhelm
    Davidson, Beverly L.
    Hyman, Bradley T.
    MOLECULAR THERAPY, 2024, 32 (04) : 536 - 537
  • [6] Polygenic Risk Score Analysis of Alzheimer’s Disease in Cases without APOE4 or APOE2 Alleles
    V. Escott-Price
    A. Myers
    M. Huentelman
    M. Shoai
    John Hardy
    The Journal of Prevention of Alzheimer's Disease, 2019, 6 : 16 - 19
  • [7] Polygenic Risk Score Analysis of Alzheimer's Disease in Cases without APOE4 or APOE2 Alleles
    Escott-Price, V
    Myers, A.
    Huentelman, M.
    Shoai, M.
    Hardy, J.
    JPAD-JOURNAL OF PREVENTION OF ALZHEIMERS DISEASE, 2019, 6 (01): : 16 - 19
  • [8] Second Generation AAV-Mediated Gene Therapy to Mitigate Risk for Alzheimer's Disease in APOE4/4Homozygotes
    Montel, Rachel A.
    Frenk, Esther
    Crystal, Ronald G.
    Stiles, Katie M.
    MOLECULAR THERAPY, 2022, 30 (04) : 395 - 395
  • [9] The pattern of distribution of extracellular matrix in ApoE2, ApoE3 and ApoE4 astrocytes. Relevance for Alzheimer's disease
    Keable, A.
    O'Neill, R.
    Johnston, D.
    Weller, R.
    Smith, N.
    Carare, R.
    NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 2018, 44 : 18 - 19
  • [10] Targeting ApoE4/ApoE receptor LRP1 in Alzheimer's disease
    Martiskainen, Henna
    Haapasalo, Annakaisa
    Kurkinen, Kaisa M. A.
    Pihlajamaki, Jussi
    Soininen, Hilkka
    Hiltunen, Mikko
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2013, 17 (07) : 781 - 794
12345